表紙
市場調查報告書

抗體藥物複合體 (ADC):連接試劑、共軛技術的全球市場 (2019-2030年)

Antibody Drug Conjugates (ADCs) - Linker and Conjugation Technologies Market, 2019-2030

出版商 ROOTS ANALYSIS 商品編碼 918376
出版日期 內容資訊 英文 310 Pages
商品交期: 最快1-2個工作天內
價格
抗體藥物複合體 (ADC):連接試劑、共軛技術的全球市場 (2019-2030年) Antibody Drug Conjugates (ADCs) - Linker and Conjugation Technologies Market, 2019-2030
出版日期: 2019年11月30日內容資訊: 英文 310 Pages
簡介

抗體藥物複合體 (ADC) ,現在有6種已通過核准藥物和超越200種的開發中的藥物,公認為標靶治療的有前途的藥物類別。其中連接試劑分子所扮演的角色和所採用的共軛技術的重要性極高,企業推動開發。

本報告提供抗體藥物複合體 (ADC)的連接試劑及共軛技術的市場調查,ADC概要,連接試劑技術及共軛技術概要,技術、類型、網站等各種區分的技術分析,開發者環境,主要企業的簡介,企業間的聯盟、合作等趨勢,各種區分的市場規模的變化、預測,未來展望等資料彙整。

第1章 序文

第2章 摘要整理

第3章 簡介

  • 本章概要
  • 抗體為基礎的治療
  • 抗體藥物複合體 (ADC)
    • ADC的零組件
  • 勝過ADC的藥理學性介入的優點
  • ADC連接試劑技術
    • 可裂解連接試劑
    • 不可裂解連接試劑
  • ADC共軛技術
    • 化學的共軛
    • 酵素的共軛
  • 未來展望

第4章 目前市場環境

  • 本章概要
  • ADC連接試劑、共軛技術:整體市場環境
    • 各技術類型
    • 各ADC世代
    • 各連接試劑類型
    • 各共軛類型
    • 各網站
    • 各藥物抗體比
    • 各專利可用性
    • 各授權活動
  • ADC連接試劑、共軛技術:開發者環境
    • 各成立年份
    • 各企業規模
    • 各地區
    • 主要ADC開發者:各技術數
  • ADC連接試劑、共軛技術:服務供應商

第5章 企業簡介

  • 本章概要
  • 主要企業:北美
    • Ambrx
    • Catalent Biologics
    • Immunomedics
    • Mersana Therapeutics
    • Seattle Genetics
    • Sutro Biopharma
  • 主要企業:歐洲、亞洲
    • Iksuda Therapeutics
    • LegoChem Biosciences
    • LinXis
    • NBE Therapeutics

第6章 聯盟、合作

  • 本章概要
  • 聯盟模式
  • 聯盟、合作清單

第7章 潛在的合作夥伴分析:各地區

第8章 技術競爭分析

  • 本章概要
  • 調查手法
  • 前提條件、主參數
  • 技術競爭力分析:各地區

第9章 專利分析

第10章 新的共軛技術平台

  • 本章概要
  • 第1代ADC技術
  • 第2代ADC技術
  • 第3代ADC技術
  • 演進分析

第11章 市場規模、預測

  • 本章概要
  • 預測手法、前提條件
  • 全球ADC連接試劑、共軛技術市場變化、預測
  • 各連接試劑類型
  • 各共軛類型
  • 主要技術的佔有率
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區

第12章 專家的見解

  • 本章概要
  • Miracogen
  • NBE Therapeutics
  • Synaffix
  • EUCODIS Bioscience

第13章 總論

第14章 附錄:圖表資料

第15章 附錄:企業、組織清單

目錄

Example Insights:

The growing interest is also reflected in the partnership activity; deals inked in the recent past were focused on a diverse range of technology platforms, involving both international and indigenous stakeholders.

Overview:

With six approved drugs, namely POLIVY™ (2019), LUMOXITI™ (2018), BESPONSA® (2017), MYLOTARG™ (2017, reapproval), KADCYLA® (2013) and ADCETRIS® (2011), and more than 200 in the pipeline (clinical / preclinical stages), antibody drug conjugates (ADCs) are now recognized as a potent class of targeted therapeutics. The success of this relatively novel class of therapeutics is attributed to the ability of lead molecules to specifically identify and eliminate disease associated cells / pathogens, consequently, addressing most of the concerns related to off target toxicities. In this context, the role of the linker molecule and the conjugation technology used is pivotal. In fact, conjugation chemistry has been shown to be directly related to the drug to antibody ratio (DAR) achieved, and thereby, governs the pharmacokinetic and pharmacodynamic properties of an ADC. Over time, a variety of other conjugated therapeutics have also been developed and are under evaluation.

Conventional conjugation technologies used for the development of ADCs exploited the superficial lysine residues that were inherent to the native antibody structure, or the inter-chain cysteine residues, for drug-linker attachment. Over time, the evolution of recombinant DNA technology and advances in conjugation techniques, have enabled researchers to significantly improve the bioconjugation process. In fact, next generation conjugation technologies use artificially integrated lysine / cysteine residues in order to improve the DAR of the resulting conjugate. Additionally, there are multiple technologies that claim to offer site-specific conjugation. There are a number of other noteworthy developments in the conjugation technologies domain, which include a variety of competent platforms based on various ligation, disulfide rebridging and protein remodeling approaches. Further, linker technologies have also evolved substantially, and there is vast array of linkers, including cleavable and non-cleavable variants, which are designed to govern drug release mechanism of conjugated therapeutic molecules.

It is worth highlighting that multiple licensing agreements / collaborations have been inked between drug developers and technology providers to advance the development of pipeline ADC candidates. Over the years, a number of start-ups / small companies, offering novel conjugation technologies, more potent cytotoxins / warheads and advanced linker chemistries, have been established to facilitate development of ADCs and other conjugated pharmaceuticals. We anticipate this niche and upcoming market to witness substantial growth over the coming years.

Scope of the Report:

The “Antibody Drug Conjugates: Linker and Conjugation Technologies Market, 2019-2030” report features an extensive study of the current landscape and the likely future opportunities within the ADC linker and conjugation technologies market, over the next 10-12 years. In addition to other elements, the report includes:

  • An overview of the overall landscape of ADC linker and conjugation technologies, featuring an in-depth analysis of the technologies, based on a number of parameters, such as type of technology, generation of the technology (first, second and third), type of linker (cleavable, non-cleavable), type of conjugation (chemical, enzymatic and others), site specificity (specific and non-specific), DAR of the ADCs developed, patent availability, and licensing activity. In addition, the chapter highlights a detailed landscape of linker and conjugation technologies developers and analysis based on parameters, such as year of establishment, company size and geographical location.
  • Elaborate profiles of prominent technology developers engaged in this domain. Each profile features a brief overview of the company, its financial information (if available), information on its technology portfolio, recent developments and an informed future outlook.
  • An analysis of the partnerships that have been established in the recent past, covering licensing agreements, product development and commercialization agreements, research and development agreements, product integration agreements, combination therapy development agreements, platform utilization agreements, and other relevant agreements.
  • A list of ADC therapeutic developers that are anticipated to partner with technology providers in future based on a detailed analysis of relevant parameters, such as availability of existing partners, availability of inhouse technology, company size (employee count), company's ADC pipeline strength, likely partners and development status of the ADC molecules.
  • A detailed competitiveness analysis of ADC linker and conjugation technologies, taking into consideration the supplier power (based on the year of establishment of developer) and key technology specifications, such as ADC generation, type of linker, DAR of the ADCs developed using the technology, availability of patent protection, number of deals signed for a particular technology (2016-2019), and popularity of the technology (in terms of the number of ADCs developed using the technology).
  • An in-depth analysis of the various patents that have been filed / granted related to linker / conjugation technologies till August 2019, taking into consideration parameters, such as patent type, publication year, issuing authority / patent offices involved, CPC symbol, emerging focus areas and leading industry / academic players (in terms of size of intellectual property portfolio). It also includes a patent benchmarking analysis and a detailed valuation analysis.

One of the key objectives of the report was to estimate the existing market size and identify potential future growth opportunities for ADC linker and conjugation technologies. Based on likely licensing deal structures and agreements that are expected to be inked in the foreseen future, we have provided an informed estimate of the evolution of the market for the period 2019-2030. The report also features the likely distribution of the current and forecasted opportunity across the [A] type of linker (cleavable, non-cleavable and both), [B] type of conjugation (chemical, enzymatic and others) [C] key technologies, and [D] key geographical regions (North America, Europe and Asia Pacific/ rest of the world). In order to account for future uncertainties and add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of discussions held with the following industry stakeholders:

  • Mary Chaohong Hu (Chief Executive Officer, Shanghai Miracogen)
  • Wouter Verhoeven (Chief Business Officer, NBE Therapeutics)
  • Floris van Delft (Chief Scientific Officer, Synaffix)
  • Jan Modregger (Head of Research & Development, EUCODIS Bioscience)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Chapter Outlines:

Chapter 2 is an executive summary of the insights captured in our research. It presents a high-level view on the current scenario within the ADC linker and conjugation technologies service providers market and its evolution in the short-mid-term and long term.

Chapter 3 provides a general introduction to ADCs, featuring details related to their various components and advantages over traditional targeted therapies. The chapter emphasizes on the role of linker and conjugation technologies in development of ADCs. Additionally, it provides an overview of the different types of linkers and conjugation technologies, highlighting their key specifications. It also features a brief discussion on anticipated future trends and how this field of research is likely to evolve over the coming decade.

Chapter 4 provides a detailed overview of the overall landscape of ADC linker and conjugation technology providers. It features an in-depth analysis of the technologies, based on a number of parameters, such as type of technology, generation of the technology (first, second and third), type of linker (cleavable, non-cleavable), type of conjugation (chemical, enzymatic and others), site specificity (specific and non-specific), DAR of the ADCs developed, patent availability, licensing activity. In addition, the chapter highlights a detailed landscape of linker and conjugation technologies developers and analysis based on parameters, such as year of establishment, company size and geographical location.

Chapter 5 provides detailed profiles of the leading stakeholders in this field. Each profile includes a brief overview of the company, its financial performance (if available), information on its technology portfolio, recent developments and an informed future outlook.

Chapter 6 features an in-depth analysis and discussion on the various collaborations and partnerships inked between the players in this market that have been established in the recent past, covering licensing agreements, product development and commercialization agreements, research and development agreements, product integration agreements, combination therapy development agreements, platform utilization agreements, and other relevant agreements.

Chapter 7 presents a list of ADC therapeutic developers that are anticipated to partner with technology providers in future based on a detailed analysis of relevant parameters, such as availability of existing partners, availability of inhouse technology, company size (employee count), company's ADC pipeline strength, likely partners and development status of the ADC molecules.

Chapter 8 presents a competitiveness analysis of the technologies based on supplier power of the developers and key technology specifications. The analysis was designed to enable stakeholder companies to compare their existing capabilities within and beyond their respective peer groups and identify opportunities to achieve a competitive edge in the industry.

Chapter 9 provides an in-depth patent analysis to provide an overview of how the industry is evolving from the R&D perspective. For this analysis, we considered those patents that have been filed / granted related to linker and conjugation technologies till August 2019. The analysis also highlights the key trends associated with these patents, across patent type, publication year, issuing authority / patent offices involved, CPC symbol, emerging focus areas and leading industry / academic players (in terms of size of intellectual property portfolio). It also includes a patent benchmarking analysis and a detailed valuation analysis.

Chapter 10 provides a review of the novel ADC conjugation technologies, highlighting the evolution of the technologies and the various approaches that have been adopted across different generations of ADCs. In addition, it presents a review of the existing competition between different type of conjugation approaches that are available / under development.

Chapter 11 presents an insightful market forecast analysis, highlighting likely growth of ADC linkers and conjugation technologies market till the year 2030, on the basis of likely licensing deal structures and agreements that are expected to be signed in the foreseen future. We have provided inputs on the likely distribution of the opportunity by type of linker (cleavable and non-cleavable), type of conjugation (chemical, enzymatic and others), key technologies and key geographical regions (North America, Europe, Asia Pacific and rest of the world).

Chapter 12 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of interviews held with Mary Chaohong Hu (Chief Executive Officer, Shanghai Miracogen), Wouter Verhoeven (Chief Business Officer, NBE Therapeutics), Floris van Delft (Chief Scientific Officer, Synaffix) and Jan Modregger (Head of Research & Development, EUCODIS Bioscience).

Chapter 13 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario. Further, it highlights the various evolutionary trends that are likely to determine the future of this segment of the ADC linker and conjugation technologies.

Chapter 14 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 15 is an appendix, which contains a list of companies and organizations mentioned in this report.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Antibody-based Therapeutics
  • 3.3 Antibody Drug Conjugates (ADCs)
    • 3.3.1 Components of ADCs
      • 3.3.1.1 Antibody
      • 3.3.1.2 Cytotoxin
      • 3.3.1.3 Linker
  • 3.4. Advantages of ADCs over Traditional Pharmacological Interventions
  • 3.5. ADC Linker Technologies
    • 3.5.1. Non-cleavable Linkers
    • 3.5.2. Cleavable Linkers
  • 3.6. ADC Conjugation Technologies
    • 3.6.1. Chemical Conjugation
    • 3.6.2. Enzymatic Conjugation
  • 3.7. Future Perspectives

4. CURRENT MARKET LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. ADC Linker and Conjugation Technologies: Overall Market Landscape
    • 4.2.1. Analysis by Type of Technology
    • 4.2.2. Analysis by ADC Generation
    • 4.2.3. Analysis by Type of Linker
    • 4.2.4. Analysis by Type of Conjugation
    • 4.2.5. Analysis by Site Specificity
    • 4.2.6. Analysis by Drug to Antibody Ratio
    • 4.2.7. Analysis by Patent Availability
    • 4.2.8. Analysis by Licensing Activity
  • 4.3. ADC Linker and Conjugation Technologies: Developer Landscape
    • 4.3.1 Analysis by Year of Establishment
    • 4.3.2 Analysis by Company Size
    • 4.3.3 Analysis by Geographical Location
    • 4.3.4 Leading ADC Developers: Analysis by Number of Technologies
    • 4.3.5 Grid Representation: Analysis by ADC Generation, Type of Linker, Company Size, and Geographical Location
    • 4.3.6 World Map Representation: Analysis by Geography
  • 4.4 ADC Linker and Conjugation Technologies: Service Providers

5. COMPANY PROFILES

  • 5.1 Chapter Overview
  • 5.2 Key Players in North America
    • 5.2.1 Ambrx
      • 5.2.1.1 Company Overview
      • 5.2.1.2 Technology Overview
      • 5.2.1.3 Recent Developments and Future outlook
    • 5.2.2 Catalent Biologics
      • 5.2.2.1 Company Overview
      • 5.2.2.2 Financial Information
      • 5.2.2.3 Technology Overview
      • 5.2.2.4 Recent Developments and Future outlook
    • 5.2.3 Immunomedics
      • 5.2.3.1 Company Overview
      • 5.2.3.2 Financial Information
      • 5.2.3.3 Technology Overview
      • 5.2.3.4 Recent Developments and Future outlook
    • 5.2.4 Mersana Therapeutics
      • 5.2.4.1 Company Overview
      • 5.2.4.2 Financial Information
      • 5.2.4.3 Technology Overview
      • 5.2.4.4 Recent Developments and Future outlook
    • 5.2.5 Seattle Genetics
      • 5.2.5.1 Company Overview
      • 5.2.5.2 Financial Information
      • 5.2.5.3 Technology Overview
      • 5.2.5.4 Recent Developments and Future outlook
    • 5.2.6 Sutro Biopharma
      • 5.2.6.1 Company Overview
      • 5.2.6.2 Financial Information
      • 5.2.6.3 Technology Overview
      • 5.2.6.4 Recent Developments and Future outlook
  • 5.3 Key Players in Europe and Asia
    • 5.3.1 Iksuda Therapeutics
      • 5.3.1.1 Company Overview
      • 5.3.1.2 Technology Overview
      • 5.3.1.3 Recent Developments and Future outlook
    • 5.3.2 LegoChem Biosciences
      • 5.3.2.1 Company Overview
      • 5.3.2.2 Technology Overview
      • 5.3.2.3 Recent Developments and Future outlook
    • 5.3.3 LinXis
      • 5.3.3.1 Company Overview
      • 5.3.3.2 Technology Overview
      • 5.3.3.3 Recent Developments and Future outlook
    • 5.3.4 NBE Therapeutics
      • 5.3.4.1 Company Overview
      • 5.3.4.2 Technology Overview
      • 5.3.4.3 Recent Developments and Future outlook

6. PARTNERSHIPS AND COLLABORATIONS

  • 6.1 Chapter Overview
  • 6.2 Partnership Models
  • 6.3 List of Partnerships and Collaborations
    • 6.3.1 Analysis by Year of Partnership
    • 6.3.2 Analysis by Type of Partnership
    • 6.3.3 Analysis by Type of Linker
    • 6.3.4 Analysis by Type of Conjugation
    • 6.3.5 Analysis by Year of Partnership and Type of Partner
    • 6.3.6 Analysis by Type of Partnership and Type of Partner
    • 6.3.7 Most Active Players: Analysis by Number of Partnerships
    • 6.3.8 Most Popular Technologies: Analysis by Number of Partnerships
    • 6.3.9 Regional Analysis
    • 6.3.10 Intercontinental and Intracontinental Agreements

7. LIKELY PARTNERS ANALYSIS

  • 7.1 Chapter Overview
  • 7.2 Scope and Methodology
  • 7.3 ADC Linker and Conjugation Technologies: Potential Strategic Partners in North America
    • 7.3.1 Most Likely Partners
    • 7.3.2 Likely Partners
    • 7.3.3 Less Likely Partners
  • 7.4 ADC Linker and Conjugation Technologies: Potential Strategic Partners in Europe
    • 7.4.1 Most Likely Partners
    • 7.4.2 Likely Partners
    • 7.4.3 Less Likely Partners
  • 7.5 ADC Linker and Conjugation Technologies: Potential Strategic Partners in Asia-Pacific
    • 7.5.1 Most Likely Partners
    • 7.5.2 Likely Partners
    • 7.5.3 Less Likely Partners

8. TECHNOLOGY COMPETITIVENESS ANALYSIS

  • 8.1 Chapter Overview
  • 8.2 Methodology
  • 8.3 Assumptions and Key Parameters
  • 8.4 Technology Competitiveness Analysis
    • 8.4.1 Technologies Developed by Companies based in North America
    • 8.4.2 Technologies Developed by Companies based in Europe
    • 8.4.3 Technologies Developed by Companies based in Asia Pacific / RoW

9. PATENT ANALYSIS

  • 9.1 Chapter Overview
  • 9.2 Scope and Methodology
  • 9.3 ADC Linker and Conjugation Technologies: Patent Portfolio
    • 9.3.1 Analysis by Publication Year
    • 9.3.2 Analysis by Issuing Authority / Patent Offices Involved
    • 9.3.3 Analysis by CPC Symbols
    • 9.3.4 Emerging Focus Areas
    • 9.3.5 Analysis by Type of Company / Organization
    • 9.3.6 Leading Assignees: Analysis by Number of Patents
  • 9.4 ADC Linker and Conjugation Technologies: Patent Benchmarking Analysis
    • 9.4.1 Analysis by Patent Characteristics
  • 9.5 ADC Linker and Conjugation Technologies: Patent Valuation Analysis

10. NOVEL CONJUGATION TECHNOLOGY PLATFORMS

  • 10.1 Chapter Overview
  • 10.2 First Generation ADC Technologies
  • 10.3 Second Generation ADC Technologies
    • 10.3.1 Cysteine and Selenocysteine Engineering
    • 10.3.2 Unnatural Amino Acid Engineering
    • 10.3.3 Amino-Terminal Serine Engineering
  • 10.4 Third Generation ADC Technologies
    • 10.4.1 Enzyme-Assisted Ligation Approaches
    • 10.4.2 Glycan Remodeling Approaches
    • 10.4.3 Ligation at Fab Nucleotide-Binding Site
    • 10.4.4 Cysteine Rebridging
    • 10.4.5 Avoiding or Limiting Retro-Michael Drug Deconjugation
  • 10.5 Evolutionary Analysis

11. MARKET SIZING AND FORECAST

  • 11.1 Chapter Overview
  • 11.2 Forecast Methodology and Key Assumptions
  • 11.3 Global ADC Linker and Conjugation Technologies Market, 2019-2030
  • 11.4 Global ADC Linker and Conjugation Technologies Market: Distribution by Type of Linker, 2019-2030
  • 11.5 Global ADC Linker and Conjugation Technologies Market: Distribution by Type of Conjugation, 2019-2030
  • 11.6 Global ADC Linker and Conjugation Technologies Market: Share of Key Technologies, 2019-2030
  • 11.7 Global ADC Linker and Conjugation Technologies Market: Distribution by Region, 2019-2030
    • 11.7.1 ADC Linker and Conjugation Technologies Market in North America, 2019-2030
      • 11.7.1.1 ADC Linker and Conjugation Technologies Market in North America: Distribution by Type of Linker, 2019-2030
      • 11.7.1.2 ADC Linker and Conjugation Technologies Market in North America: Distribution by Type of Conjugation, 2019-2030
      • 11.7.1.3 ADC Linker and Conjugation Technologies Market in North America: Share of Key Technologies, 2019-2030
    • 11.7.2 ADC Linker and Conjugation Technologies Market in Europe, 2019-2030
      • 11.7.2.1 ADC Linker and Conjugation Technologies Market in Europe: Distribution by Type of Linker, 2019-2030
      • 11.7.2.2 ADC Linker and Conjugation Technologies Market in Europe: Distribution by Type of Conjugation, 2019-2030
      • 11.7.2.3 ADC Linker and Conjugation Technologies Market in Europe: Share of Key Technologies, 2019-2030
    • 11.7.3 ADC Linker and Conjugation Technologies Market in Asia Pacific, 2019-2030
      • 11.7.3.1 ADC Linker and Conjugation Technologies Market in Asia Pacific: Distribution by Type of Linker, 2019-2030
      • 11.7.3.2 ADC Linker and Conjugation Technologies Market in Asia Pacific: Distribution by Type of Conjugation, 2019-2030
      • 11.7.3.3 ADC Linker and Conjugation Technologies Market in Asia Pacific: Share of Key Technologies, 2019-2030

12. EXECUTIVE INSIGHTS

  • 12.1 Chapter Overview
  • 12.2 Miracogen
    • 12.2.1 Company Snapshot
    • 12.2.2 Interview Transcript: Mary Hu, Chief Executive Officer
  • 12.3 NBE Therapeutics
    • 12.3.1 Company Snapshot
    • 12.3.2 Interview Transcript: Wouter Verhoeven, Chief Business Officer
  • 12.4 Synaffix
    • 12.4.1 Company Snapshot
    • 12.4.2 Interview Transcript: Floris van Delft, Chief Scientific Officer
  • 12.5 EUCODIS Bioscience
    • 12.5.1 Company Snapshot
    • 12.5.2 Interview Transcript: Jan Modregger, Head of Research & Development

13. CONCLUDING REMARKS

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

  • Figure 3.1. Components of ADCs
  • Figure 3.2. Types of Linkers
  • Figure 4.1. ADC Linker and Conjugation Technologies: Distribution by Type of Technology
  • Figure 4.2. ADC Linker and Conjugation Technologies: Distribution by ADC Generation
  • Figure 4.3. ADC Linker and Conjugation Technologies: Distribution by Type of Linker
  • Figure 4.4. ADC Linker and Conjugation Technologies: Distribution by Type of Conjugation
  • Figure 4.5. ADC Linker and Conjugation Technologies: Distribution by Site Specificity
  • Figure 4.6. ADC Linker and Conjugation Technologies: Distribution by Drug to Antibody Ratio
  • Figure 4.7. ADC Linker and Conjugation Technologies: Distribution by Patent Availability
  • Figure 4.8. ADC Linker and Conjugation Technologies: Distribution by Licensing Activity
  • Figure 4.9. ADC Linker and Conjugation Technologies: Distribution by Year of Establishment
  • Figure 4.10. ADC Linker and Conjugation Technologies: Distribution by Company Size
  • Figure 4.11. ADC Linker and Conjugation Technologies: Distribution by Geographical Location
  • Figure 4.12. Leading ADC Developers: Distribution by Number of Technologies
  • Figure 4.13. Grid Representation: Distribution by ADC Generation, Type of Linker, Company Size, and Geographical Location
  • Figure 4.14. World Map Representation: Analysis by Geography
  • Figure 5.1. Catalent Biologics: Annual Revenues, 2014- 2019 (USD Million)
  • Figure 5.2. Immunomedics: Annual Revenues, 2014-2018 (USD Million)
  • Figure 5.3. Mersana Therapeutics: Annual Revenues, 2015-2019 (H3) (USD Million)
  • Figure 5.4. Seattle Genetics: Annual Revenues, 2014-2019 (H1) (USD Million)
  • Figure 5.5. Sutro Biopharma: Annual Revenues, 2016- 2019 (H3) (USD Million)
  • Figure 6.1. Partnerships and Collaborations: Cumulative Year-wise Trend, 2014-2019
  • Figure 6.2. Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 6.3. Partnerships and Collaborations: Year-wise Trend by Type of Partnership 2014-2019.
  • Figure 6.4. Partnerships and Collaborations: Distribution by Type of Linker and Type of Partnership
  • Figure 6.5. Partnerships and Collaborations: Distribution by Type of Conjugation and Type of Partnership
  • Figure 6.6. Partnerships and Collaborations: Year-wise Trend for Type of Partner
  • Figure 6.7. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
  • Figure 6.8. Most Active Players: Distribution by Number of Partnerships
  • Figure 6.9. Most Popular Technologies: Distribution by Number of Partnerships
  • Figure 6.10. Partnership and Collaborations: Regional Distribution
  • Figure 6.11. Partnerships and Collaborations: Intercontinental and Intracontinental Deals
  • Figure 8.1. Competitiveness Analysis: Technologies Developed by Companies Based in North America
  • Figure 8.2. Competitiveness Analysis: Technologies Developed by Companies Based in Europe
  • Figure 8.3. Competitiveness Analysis: Technologies Developed by Companies Based in Asia Pacific / RoW
  • Figure 9.1. Patent Analysis: Distribution by Type of Patent
  • Figure 9.2. Patent Analysis: Cumulative Year-wise Trend, 2016-2019
  • Figure 9.3. Patent Analysis: Distribution by Issuing Authority / Patent Offices Involved
  • Figure 9.4. Patent Analysis: Distribution by CPC Symbols
  • Figure 9.5. Patent Analysis: Emerging Focus Areas
  • Figure 9.6. Patent Analysis: Cumulative Distribution by Company / Organization
  • Figure 9.7. Leading Industry Players in Terms of Number of Patents
  • Figure 9.8. Leading Non-Industry Players in Terms of Number of Patents
  • Figure 9.9. Leading Assignees: Distribution by Number of Patents
  • Figure 9.10. Patent Benchmarking: Roche and AbbVie (based on Patent Characteristics)
  • Figure 9.11. Patent Benchmarking: Leading Industry Players (based on Patent Characteristics)
  • Figure 10.1. Evolution of ADC technology Platforms
  • Figure 10.2. ADC Conjugation Platforms: Technology Landscape
  • Figure 11.1. Global ADC Linker and Conjugation Technologies Market, 2019-2030 (USD Billion)
  • Figure 11.2. Global ADC Linker and Conjugation Technologies Market: Distribution by Type of Linker, 2019-2030 (USD Billion)
  • Figure 11.3. Global ADC Linker and Conjugation Technologies Market: Distribution by Type of Conjugation, 2019-2030 (USD Billion)
  • Figure 11.4. Global ADC Linker and Conjugation Technologies Market: Share of Key Technologies, 2019-2030 (USD Billion)
  • Figure 11.5. Global ADC Linker and Conjugation Technologies Market: Distribution by Region, 2019-2030 (USD Billion)
  • Figure 11.6. ADC Linker and Conjugation Technologies Market in North America, 2019-2030 (USD Billion)
  • Figure 11.7. ADC Linker and Conjugation Technologies Market in North America: Distribution by Type of Linker, 2019-2030 (USD Billion)
  • Figure 11.8. ADC Linker and Conjugation Technologies Market in North America: Distribution by Type of Conjugation, 2019-2030 (USD Billion)
  • Figure 11.9. ADC Linker and Conjugation Technologies Market in North America: Share of Key Technologies, 2019-2030 (USD Billion)
  • Figure 11.10. ADC Linker and Conjugation Technologies Market in Europe, 2019-2030 (USD Billion)
  • Figure 11.11. ADC Linker and Conjugation Technologies Market in Europe: Distribution by Type of Linker, 2019-2030 (USD Billion)
  • Figure 11.12. ADC Linker and Conjugation Technologies Market in Europe: Distribution by Type of Conjugation, 2019-2030 (USD Billion)
  • Figure 11.13. ADC Linker and Conjugation Technologies Market in Europe: Share of Key Technologies, 2019-2030 (USD Billion)
  • Figure 11.14. ADC Linker and Conjugation Technologies Market in Asia Pacific, 2019-2030 (USD Billion)
  • Figure 11.15. ADC Linker and Conjugation Technologies Market in Asia Pacific: Distribution by Type of Linker, 2019-2030 (USD Billion)
  • Figure 11.16. ADC Linker and Conjugation Technologies Market in Asia Pacific: Distribution by Type of Conjugation, 2019-2030 (USD Billion)
  • Figure 11.17. ADC Linker and Conjugation Technologies Market in Asia Pacific: Share of Key Technologies, 2019-2030 (USD Billion)

List of Tables

  • Table 3.1. List of Approved Monoclonal Antibody Therapies
  • Table 3.2. Commonly Used Cytotoxins in ADC Therapeutics
  • Table 4.1. ADC Linker and Conjugation Technologies: Overall Market Landscape
  • Table 5.1. Leading ADC Linker and Conjugation Technology Companies
  • Table 5.2. Ambrx: Company Overview
  • Table 5.3. Ambrx: Drug Portfolio based on ADC Technology
  • Table 5.4. Ambrx: Recent Developments and Future Outlook
  • Table 5.5. Catalent Biologics: Company Overview
  • Table 5.6. Catalent Biologics: Drug Portfolio based on ADC Technology
  • Table 5.7. Catalent Biologics: Recent Developments and Future Outlook
  • Table 5.8. Immunomedics: Company Overview
  • Table 5.9. Immunomedics: Drug Portfolio based on ADC Technology
  • Table 5.10. Immunomedics: Recent Developments and Future Outlook
  • Table 5.11. Mersana Therapeutics: Company Overview
  • Table 5.12. Mersana Therapeutics: Drug Portfolio based on ADC Technology
  • Table 5.13. Mersana Therapeutics: Recent Developments and Future Outlook
  • Table 5.14. Seattle Genetics: Company Overview
  • Table 5.15. Seattle Genetics: Drugs Drug Portfolio based on ADC Technology
  • Table 5.16. Seattle Genetics: Recent Developments and Future Outlook
  • Table 5.17. Sutro Biopharma: Company Overview
  • Table 5.18. Sutro Biopharma: Drug Portfolio based on ADC Technology
  • Table 5.19. Sutro Biopharma: Recent Developments and Future Outlook
  • Table 5.20. Iksuda Therapeutics: Company Overview
  • Table 5.21. Iksuda Therapeutics: Drug Portfolio based on ADC Technology
  • Table 5.22. Iksuda Therapeutics: Recent Developments and Future Outlook
  • Table 5.23. LegoChem Biosciences: Company Overview
  • Table 5.24. LegoChem Biosciences: Drug Portfolio based on ADC Technology
  • Table 5.25. LegoChem Biosciences: Recent Developments and Future Outlook
  • Table 5.26. LinXis: Company Overview
  • Table 5.27. LinXis: Drug Portfolio based on ADC Technology
  • Table 5.28. LinXis: Recent Developments and Future Outlook
  • Table 5.29. NBE Therapeutics: Company Overview
  • Table 5.30. NBE Therapeutics: Drug Portfolio based on ADC Technology
  • Table 5.31. NBE Therapeutics: Recent Developments and Future Outlook
  • Table 6.1. ADC Linker and Conjugation Technologies: Partnerships and Collaborations, 2014-2019
  • Table 7.1. North America: Most Likely Partners
  • Table 7.2. North America: Likely Partners
  • Table 7.3. North America: Less Likely Partners
  • Table 7.4. Europe: Most Likely Partners
  • Table 7.5. Europe: Likely Partners
  • Table 7.6. Europe: Less Likely Partners
  • Table 7.7. Asia-Pacific: Most Likely Partners
  • Table 7.8. Asia-Pacific: Likely Partners
  • Table 7.9. Asia-Pacific: Less Likely Partners
  • Table 9.1. Patent Analysis: CPC Symbol Definitions
  • Table 9.2. Patent Analysis: Popular CPC Symbols
  • Table 9.3. Patent Analysis: List of Top CPC Symbols
  • Table 9.4. Patent Analysis: List of Leading Assignees
  • Table 9.5. Patent Analysis: Benchmarking Analysis Summary
  • Table 9.6. Patent Analysis: List of Leading Patents (by Highest Relative Valuation)
  • Table 10.1. Second Generation ADC Technologies: Cysteine and Selenocysteine Engineering
  • Table 10.2. Second Generation ADC Technologies: Unnatural Amino Acid Engineering
  • Table 10.3. Second Generation ADC Technologies: Amino-terminal Engineered Serine
  • Table 10.4. Third Generation ADC Technologies: Enzyme-Assisted Ligation Approaches
  • Table 10.5. Third Generation ADC Technologies: Glycan Remodeling Approaches
  • Table 10.6. Third Generation ADC Technologies: Enzyme-Assisted Ligation Approaches
  • Table 10.7. Third Generation ADC Technologies: Cysteine Rebridging
  • Table 10.8. Third Generation ADC Technologies: Avoiding or Limiting Retro-Michael Drug Deconjugation
  • Table 12.1. Miracogen: Key Highlights
  • Table 12.2. NBE Therapeutics: Key Highlights
  • Table 12.3. Synaffix: Key Highlights
  • Table 12.4. EUCODIS Bioscience: Key Highlights
  • Table 14.1. ADC Linker and Conjugation Technologies: Distribution by Type of Technology
  • Table 14.2. ADC Linker and Conjugation Technologies: Distribution by ADC Generation
  • Table 14.3. ADC Linker and Conjugation Technologies: Distribution by Type of Linker
  • Table 14.4. ADC Linker and Conjugation Technologies: Distribution by Type of Conjugation
  • Table 14.5. ADC Linker and Conjugation Technologies: Distribution by Site Specificity
  • Table 14.6. ADC Linker and Conjugation Technologies: Distribution by Drug to Antibody Ratio
  • Table 14.7. ADC Linker and Conjugation Technologies: Distribution by Patent Availability
  • Table 14.8. ADC Linker and Conjugation Technologies: Distribution by Licensing Activity
  • Table 14.9. ADC Linker and Conjugation Technologies: Distribution by Year of Establishment
  • Table 14.10. ADC Linker and Conjugation Technologies: Distribution by Company Size
  • Table 14.11. ADC Linker and Conjugation Technologies: Distribution by Geographical Location
  • Table 14.12. Leading ADC Developers: Distribution by Number of Technologies
  • Table 14.13. Catalent Biologics: Annual Revenues, 2014- 2019 (USD Million)
  • Table 14.14. Immunomedics: Annual Revenues, 2014-2018 (USD Million)
  • Table 14.15. Mersana Therapeutics: Annual Revenues, 2015-2019 (H3) (USD Million)
  • Table 14.16. Seattle Genetics: Annual Revenues, 2014-2019 (H1) (USD Million)
  • Table 14.17. Sutro Biopharma: Annual Revenues, 2016- 2019 (H3) (USD Million)
  • Table 14.18. Partnerships and Collaborations: Cumulative Year-wise Trend, 2014-2019
  • Table 14.19. Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 14.20. Partnerships and Collaborations: Year-wise Trend by Type of Partnership
  • Table 14.21. Partnerships and Collaborations: Distribution by Type of Linker and Type of Partnership
  • Table 14.22. Partnerships and Collaborations: Distribution by Type of Conjugation and Type of Partnership
  • Table 14.23. Partnerships and Collaborations: Year-wise Trend for Type of Partner
  • Table 14.24. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
  • Table 14.25. Most Active Players: Distribution by Number of Partnerships
  • Table 14.26. Most Popular Technologies: Distribution by Number of Partnerships
  • Table 14.27. Partnership and Collaborations: Regional Distribution
  • Table 14.28. Patent Analysis: Distribution by Type of Patent
  • Table 14.29. Patent Analysis: Cumulative Year-wise Trend, 2016-2019
  • Table 14.30. Patent Analysis: Distribution by Issuing Authority / Patent Offices Involved
  • Table 14.31. Patent Analysis: Distribution by CPC Symbols
  • Table 14.32. Patent Analysis: Emerging Focus Areas
  • Table 14.33. Patent Analysis: Cumulative Distribution by Company / Organization
  • Table 14.34. Leading Industry Players in Terms of Number of Patents
  • Table 14.35. Leading Non-Industry Players in Terms of Number of Patents
  • Table 14.36. Leading Assignees: Distribution by Number of Patents
  • Table 14.37. Global ADC Linker and Conjugation Technologies Market, 2019-2030 (USD Billion)
  • Table 14.38. Global ADC Linker and Conjugation Technologies Market: Distribution by Type of Linker, 2019-2030 (USD Billion)
  • Table 14.39. Global ADC Linker and Conjugation Technologies Market: Distribution by Type of Conjugation, 2019-2030 (USD Billion)
  • Table 14.40. Global ADC Linker and Conjugation Technologies Market: Share of Key Technologies, 2019-2030 (USD Billion)
  • Table 14.41. Global ADC Linker and Conjugation Technologies Market: Distribution by Region, 2019-2030 (USD Billion)
  • Table 14.42. ADC Linker and Conjugation Technologies Market in North America, 2019-2030 (USD Billion)
  • Table 14.43 ADC Linker and Conjugation Technologies Market in North America: Distribution by Type of Linker, 2019-2030 (USD Billion)
  • Table 14.44 ADC Linker and Conjugation Technologies Market in North America: Distribution by Type of Conjugation, 2019-2030 (USD Billion)
  • Table 14.45. ADC Linker and Conjugation Technologies Market in North America: Share of Key Technologies, 2019-2030 (USD Billion)
  • Table 14.46. ADC Linker and Conjugation Technologies Market in Europe, 2019-2030 (USD Billion)
  • Table 14.47. ADC Linker and Conjugation Technologies Market in Europe: Distribution by Type of Linker, 2019-2030 (USD Billion)
  • Table 14.48. ADC Linker and Conjugation Technologies Market in Europe: Distribution by Type of Conjugation, 2019-2030 (USD Billion)
  • Table 14.49. ADC Linker and Conjugation Technologies Market in Europe: Share of Key Technologies, 2019-2030 (USD Billion)
  • Table 14.50. ADC Linker and Conjugation Technologies Market in Asia Pacific, 2019-2030 (USD Billion)
  • Table 14.51. ADC Linker and Conjugation Technologies Market in Asia Pacific: Distribution by Type of Linker, 2019-2030 (USD Billion)
  • Table 14.52. ADC Linker and Conjugation Technologies Market in Asia Pacific: Distribution by Type of Conjugation, 2019-2030 (USD Billion)
  • Table 14.53. ADC Linker and Conjugation Technologies Market in Asia Pacific: Share of Key Technologies, 2019-2030 (USD Billion)

List of Companies

The following companies and organizations are mentioned in the report.

  • 1. 3P Biopharmaceuticals
  • 2. 3SBio
  • 3. AbbVie
  • 4. AbGenomics
  • 5. ABL Bio
  • 6. Abnova
  • 7. Abzena
  • 8. ACES Pharma
  • 9. ADC Biotechnology
  • 10. ADC Therapeutics
  • 11. Advanced Proteome Therapeutics
  • 12. Affinity Life Sciences
  • 13. AGC Biologics
  • 14. Agensys
  • 15. Ajinomoto
  • 16. Ajinomoto Bio-Pharma Services
  • 17. Albumedix
  • 18. Alexion Pharmaceuticals
  • 19. Allergan
  • 20. Alpha Cancer Technologies
  • 21. Alta Partners
  • 22. Alteogen
  • 23. Ambrx
  • 24. Amgen
  • 25. Angiex
  • 26. Antikor Biopharma
  • 27. Araris Biotech
  • 28. Asana BioSciences
  • 29. Astellas Pharma
  • 30. AstraZeneca
  • 31. Avacta Life Sciences
  • 32. Bayer
  • 33. BeiGene
  • 34. BioAtla
  • 35. BioCapital
  • 36. Biogen
  • 37. BioLegend
  • 38. BioMed Valley Discoveries
  • 39. BioOutsource
  • 40. Bio-Rad Laboratories
  • 41. Bio-Synthesis
  • 42. Biotechnique
  • 43. Biotest
  • 44. Bio-Thera Solutions
  • 45. BlinkBio
  • 46. Bliss Biopharmaceutical
  • 47. BOC Sciences
  • 48. Boehringer Ingelheim
  • 49. Boster Biological Technology
  • 50. Bristol-Myers Squibb
  • 51. BSP Pharmaceuticals
  • 52. Cancer Research UK
  • 53. Capra Science Antibodies
  • 54. CARBOGEN AMCIS
  • 55. Cascadian Therapeutics
  • 56. Catalent Biologics
  • 57. Celgene
  • 58. CellMosaic
  • 59. Cell Signalling Technology
  • 60. Cellerant Therapeutics
  • 61. Celltrion
  • 62. Centrose
  • 63. Cerbios-Pharma
  • 64. Chugai Pharmaceutical
  • 65. Cisbio
  • 66. Clovis Oncology
  • 67. Concortis Biotherapeutics
  • 68. Corixa
  • 69. Creative Biolabs
  • 70. Creative Diagonostics
  • 71. Creative peptides
  • 72. CSPC Pharmaceutical Group
  • 73. CureMeta
  • 74. Cytogen
  • 75. CytomX Therapeutics
  • 76. Daiichi Sankyo
  • 77. Dalton Pharma Services
  • 78. Debiopharm Group
  • 79. Dyax
  • 80. Eisai
  • 81. Elan Pharmaceuticals
  • 82. Eli Lilly
  • 83. Elusys Therapeutics
  • 84. EMD Serono
  • 85. Envigo
  • 86. Esperance Pharmaceuticals
  • 87. EUCODIS Bioscience
  • 88. Eventide Asset Management
  • 89. Everest Biotech
  • 90. Everest Medicines
  • 91. Exelixis
  • 92. Expedeon
  • 93. Femtogenix
  • 94. Fleet Bioprocessing
  • 95. Formation Biologics
  • 96. Formosa Laboratories
  • 97. Fortis Therapeutics
  • 98. Fosun Pharma
  • 99. GamaMabs Pharma
  • 100. Genentech
  • 101. Genmab
  • 102. Genovis
  • 103. GenScript
  • 104. Genzyme
  • 105. GlaxoSmithKline
  • 106. Glycotope
  • 107. Glythera
  • 108. Goodwin Biotechnology
  • 109. GT Biopharma
  • 110. Hangzhou DAC Biotech
  • 111. Heidelberg Pharma
  • 112. Hengrui Medicine
  • 113. Human Genome Sciences
  • 114. iBioSource
  • 115. Iconic Therapeutics
  • 116. Iksuda Therapeutics
  • 117. ImClone Systems
  • 118. ImmunoBiochem
  • 119. ImmunoGen
  • 120. Immunomedics
  • 121. Innate Pharma
  • 122. Innovate UK
  • 123. IntoCell
  • 124. IONTAS
  • 125. iProgen Biotech
  • 126. Iterum Therapeutics
  • 127. Janssen Biotech
  • 128. Johnson & Johnson
  • 129. Johnson Matthey
  • 130. Kairos Therapeutics
  • 131. KLUS Pharma
  • 132. Kyowa Hakko Kirin
  • 133. LakePharma
  • 134. LegoChem Bioscienses
  • 135. Leinco Technologies
  • 136. Leukemia & Lymphoma Society
  • 137. Levena Biopharma
  • 138. Life Technologies
  • 139. Light Chain Bioscience
  • 140. Lilly Ventures
  • 141. LinXis
  • 142. MabPlex
  • 143. MabSpace Biosciences
  • 144. MabVax Therapeutics
  • 145. MacroGenics
  • 146. Magenta Therapeutics
  • 147. Maine Biotechnology
  • 148. MediaPharma
  • 149. MedImmune
  • 150. Meditope Biosciences
  • 151. MedKoo Biosciences
  • 152. Memorial Sloan Kettering Cancer Center
  • 153. Menarini Group
  • 154. Merck
  • 155. Mersana Therapeutics
  • 156. Millennium Pharmaceuticals
  • 157. Mitsubishi Tanabe Pharma
  • 158. MorphoSys
  • 159. Morphotek
  • 160. MuseChem
  • 161. NanoValent Pharmaceuticals
  • 162. National Research Council of Canada
  • 163. NBE-Therapeutics
  • 164. NeoRx
  • 165. Nexthera Capital
  • 166. Nordic Nanovector
  • 167. Noria Pharmaceuticals
  • 168. Novartis
  • 169. NovaTeinBio Novimmune
  • 170. NovoCodex Biopharmaceuticals
  • 171. Novozymes
  • 172. OBI Pharma
  • 173. OcellO
  • 174. OGD2 Pharma
  • 175. Oncolinx
  • 176. Oncomatryx Biopharma
  • 177. Oncotec Pharma Produktion
  • 178. Organon Teknika
  • 179. OriGene Technologies
  • 180. Oxford BioTherapeutics
  • 181. Palatin Technologies
  • 182. Pfizer
  • 183. Pharmaron
  • 184. Philochem
  • 185. Pierre Fabre
  • 186. Piramal Pharma Solutions
  • 187. ProBioGen
  • 188. Progenics Pharmaceuticals
  • 189. ProteoGenix
  • 190. Puma Biotechnology
  • 191. Rakuten Medical
  • 192. Recepta Biopharma
  • 193. Redwood Bioscience
  • 194. Regeneron Pharmaceuticals
  • 195. RemeGen
  • 196. Roche
  • 197. Rockland Immunochemicals
  • 198. SafeBridge Consultants
  • 199. Samsung Medical Center
  • 200. Sanofi
  • 201. Seattle Genetics
  • 202. Seramun Diagnostica
  • 203. Servier
  • 204. Sesen Bio
  • 205. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
  • 206. Shanghai Jiaolian Medicine Research and Development
  • 207. Shanghai Miracogen
  • 208. Shenogen Pharma
  • 209. Shire
  • 210. Siamab Therapeutics
  • 211. Skyline Ventures
  • 212. Sorrento Therapeutics
  • 213. SOTIO
  • 214. SouthernBiotech
  • 215. Sun Pharmaceutical Industries
  • 216. Sunomix Biosciences
  • 217. Surveyor Capital
  • 218. Sutro Biopharma
  • 219. SV Health Investors
  • 220. Swedish Orphan Biovitrum (Sobi)
  • 221. Synaffix
  • 222. Syngene International
  • 223. Synthon
  • 224. TaiMed Biologics
  • 225. Takeda Pharmaceutical
  • 226. TBD-Biodiscovery
  • 227. Teresi Pharmaceuticals
  • 228. Teva Pharmaceutical
  • 229. The Johns Hopkins University School of Medicine
  • 230. The University of Texas MD Anderson Cancer Center
  • 231. Theratechnologies
  • 232. Thermo Fisher Scientific
  • 233. ThioLogics
  • 234. TOT BIOPHARM
  • 235. Triphase Accelerator
  • 236. Tsuchikama Laboratory
  • 237. UCB
  • 238. Ultragenyx Pharmaceutical
  • 239. United Therapeutics
  • 240. UW Carbone Cancer Center
  • 241. Vaccinex
  • 242. Valeant Pharmaceuticals
  • 243. VelosBio
  • 244. Vida Ventures
  • 245. Visterra
  • 246. WuXi Biologics
  • 247. Wyeth
  • 248. Xintela
  • 249. Yale Cancer Center
  • 250. Y-Biologics
  • 251. Zhejiang Hisun Pharmaceutical
  • 252. Zymeworks